Results 121 to 130 of about 699,897 (304)

46 Do we know it when we see it? Moving toward a systematized identification of translational science

Journal of Clinical and Translational Science
Objectives/Goals: We aim to establish a systematic approach to distinguish translational science from translational research. Our goal is to create a simple tool that would enable individuals with different backgrounds and levels of expertise to readily ...
Melissa Vaught, Paul J. Martin
doaj   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

UMCCTS Newsletter, December 2015 [PDF]

, 2015
This is the December 2015 issue of the UMass Center for Clinical and Translational Science Newsletter containing news and events of ...
UMass Center for Clinical and Translational Science
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Steps toward developing an algorithm to facilitate recognition of translational science

Journal of Clinical and Translational Science
Introduction: In preparing for our Clinical and Translational Science Award (CTSA) UM1 application, we recognized the need to develop a shared understanding of the distinctions between translational science (TS) and translational research (TR).
Paul J. Martin, Brian E. Saelens, Theodore Johnson, Mark Harniss, Tumaini R. Coker, Erin Abu-Rish Blakeney, Nina Isoherranen, Tong Sun, Nisha Bansal, Stephanie J. Lee, John Amory, Naomi Kaku, Melissa Vaught   +12 more
doaj   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

The role of information science within the clinical translational science ecosystem [PDF]

Academic health sciences libraries (“libraries”) offer services that span the entire research lifecycle, positioning them as natural partners in advancing clinical and translational science.
Dexter, Nadine, Aspinall, Erinn E, Aspinall, Erinn E., Renae Barger, Tao, Donghua, Holmes, Kristi, Bart Ragon, Micquel Little, Donghua Tao, Jennifer Muilenburg, Muilenburg, Jennifer, Haberstroh, Amanda, Sevetson, Erika, Kern, Barbara, Alisa Surkis, Amanda Haberstroh, Terrie R. Wheeler, Hinton, Elizabeth, Werner, Debra A, Elizabeth C. Whipple, Deaver, Jill, Glenn, Emily J., Nadine Dexter, Seymour, Anne, Debra A. Werner, Contaxis, Nicole, Glenn, Emily J, Jill Deaver, Keith Pickett, Little, Micquel, Anne Seymour, von Isenburg, Megan, Whipple, Elizabeth C., Ragon, Bart, Kristi Holmes, Werner, Debra A., Melissa L. Rethlefsen, Wheeler, Terrie R., Wheeler, Terrie R, Nicole Contaxis, Erika Sevetson, Whipple, Elizabeth C, Rethlefsen, Melissa L., Barger, Renae, Megan von Isenburg, Emily J. Glenn, Erinn E. Aspinall, Surkis, Alisa, Rethlefsen, Melissa L, Pickett, Keith, Barbara Kern, Elizabeth Hinton   +51 more
core   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source